Inhibition of histone deacetylase 6 restores innate immune cells in the bone marrow in a lethal septic model

Journal of Trauma and Acute Care Surgery

Volumn 80, Issue 1, 2016, Pages 34-41

  Zhao, Ting ^a   Li, Yongqing ^a   Liu, Baoling ^a   Pan, Baihong ^a   Cheng, Xin ^a   Georgoff, Patrick ^a   Alam, Hasan B ^a  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Bone marrow; HDAC6; Innate immune cells; Mice; Sepsis

Indexed keywords

CD11B ANTIGEN; CD3 ANTIGEN; FLUORESCEIN ISOTHIOCYANATE; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; TUBASTATIN A; UNCLASSIFIED DRUG; HYDROXAMIC ACID; INDOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BACTERIAL CLEARANCE; BONE MARROW CELL; CELL POPULATION; CELL SURVIVAL; CELL SUSPENSION; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME INHIBITION; ERYTHROCYTE; FEMUR; FLOW CYTOMETER; FLOW CYTOMETRY; INNATE IMMUNITY; MACROPHAGE; MALE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SHAM PROCEDURE; SINGLE CELL ANALYSIS; T LYMPHOCYTE; TIBIA; ANIMAL; BONE MARROW; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; LIGATION; MORTALITY; PERITONITIS; PUNCTURE; RANDOMIZATION;

ANIMALS; BONE MARROW; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; IMMUNITY, INNATE; INDOLES; LIGATION; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; NEUTROPHILS; PERITONITIS; PUNCTURES; RANDOM ALLOCATION; SEPSIS;

EID: 84952714970     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0000000000000897     Document Type: Conference Paper

References (28)

1. Wenzel RP, Edmond MB. Septic shockVevaluating another failed treatment. N Engl J Med. 2012;366(22):2122-2124.
2. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gardlund B, Marshall JC, Rhodes A, Artigas A, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366(22): 2055-2064.
3. Zou H, Wu Y, Navre M, Sang BC. Characterization of the two catalytic domains in histone deacetylase 6. Biochem Biophys Res Commun. 2006;341(1):45-50.
4. Rivieccio MA, Brochier C, Willis DE, Walker BA, D'Annibale MA, McLaughlin K, Siddiq A, Kozikowski AP, Jaffrey SR, Twiss JL, et al. HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc Natl Acad Sci U S A. 2009;106(46):19599-19604.
5. Aldana-Masangkay GI, Sakamoto KM. The role of HDAC6 in cancer. J Biomed Biotechnol. 2011;2011:875824.
6. Butler KV, Kalin J, Brochier C, Vistoli G, Langley B, Kozikowski AP. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, Tubastatin A. J Am Chem Soc. 2010;132(31): 10842-10846.
7. Li Y, Zhao T, Liu B, Halaweish I, Mazitschek R, Duan X, Alam HB. Inhibition of histone deacetylase 6 improves long-term survival in a lethal septic model. J Trauma Acute Care Surg. 2015;78(2):378-385.
8. Zhao T, Li Y, Liu B, Halaweish I, Mazitschek R, Alam HB. Selective inhibition of histone deacetylase 6 alters the composition of circulating blood cells in a lethal septic model. J Surg Res. 2014;190(2):647-654.
9. Zhao T, LiY, Bronson RT, Liu B, VelmahosGC,AlamHB. Selective histone deacetylase-6 inhibition attenuates stress responses and prevents immune organ atrophy in a lethal septic model. Surgery. 2014;156(2):235-242.
10. Zhao T, Li Y, Liu B, Liu Z, Chong W, Duan X, Deperalta DK, Velmahos GC, Alam HB. Novel pharmacologic treatment attenuates septic shock and improves long-term survival. Surgery. 2013;154(2):206-213.
11. Zhao T, Li Y, Liu B, Bronson RT, Halaweish I, Alam HB. Histone deacetylase III as a potential therapeutic target for the treatment of lethal sepsis. J Trauma Acute Care Surg. 2014;77(6):913-919.
12. Rauch PJ, Chudnovskiy A, Robbins CS,Weber GF, Etzrodt M, Hilgendorf I, Tiglao E, Figueiredo JL, Iwamoto Y, Theurl I, et al. Innate response activator B cells protect against microbial sepsis. Science. 2012;335(6068): 597-601.
13. Kim HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 2011;3: 166-179.
14. Li Y, Alam HB. Modulation of acetylation: creating a pro-survival and anti-inflammatory phenotype in lethal hemorrhagic and septic shock. J Biomed Biotechnol. 2011;2011:523481.
15. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP. HDAC6 is a microtubule-associated deacetylase. Nature. 2002;417(6887):455-458.
16. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005;280(29):26729-26734.
17. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell. 2005;18(5):601-607.
18. Triantafilou M, Triantafilou K. Heat-shock protein 70 and heat-shock protein 90 associate with Toll-like receptor 4 in response to bacterial lipopolysaccharide. Biochem Soc Trans. 2004;32(Pt 4):636-639.
19. Eklund EA, Platanias LC. Inhibition of histone deacetylase 6 as a therapeutic strategy for acute lymphocytic leukemia. Leuk Lymphoma. 2011; 52(8):1421-1422.
20. Hackanson B, Rimmele L, BenkiQer M, Abdelkarim M, Fliegauf M, Jung M, Lübbert M. HDAC6 as a target for antileukemic drugs in acute myeloid leukemia. Leuk Res. 2012;36(8):1055-1062.
21. Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 2012;119(11):2579-2589.
22. Schulz R, Marchenko ND, Holembowski L, Fingerle-Rowson G, Pesic M, Zender L, Dobbelstein M, Moll UM. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J Exp Med. 2012;209(2):275-289.
23. Lemon DD, Horn TR, Cavasin MA, Jeong MY, Haubold KW, Long CS, Irwin DC, McCune SA, Chung E, Leinwand LA, et al. Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension. J Mol Cell Cardiol. 2011;51(1):41-50.
24. Underhill DM, Ozinsky A. Phagocytosis of microbes: complexity in action. Ann Rev Immunol. 2002;20:825-852.
25. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348(2):138-150.
26. Boomer JS, To K, Chang KC, Takasu O, Osborne DF,Walton AH, Bricker TL, Jarman SD 2nd, Kreisel D, Krupnick AS, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011; 306(23):2594-2605.
27. Wang JC, Chen C, Dumlao T, Naik S, Chang T, Xiao YY, Sominsky I, Burton J. Enhanced histone deacetylase enzyme activity in primary myelofibrosis. Leuk Lymphoma. 2008;49(12):2321-2327.
28. Chen SS, Jenkins AJ, Majewski H. Elevated plasma prostaglandins and acetylated histone in monocytes in type 1 diabetes patients. Diabet Med. 2009;26(2):182-186.